Tag Archives: Biomea Fusion

Biomea Ph2 T2DM Results; AZ Ph3 Baxdrostat Data; Ionis 2025 Innovation Day; New Hanmi Ph2 Triple Agonist Study; MannKind Completes scPharmaceuticals Acquisition; Fractyl Health Preclinical Gene Therapy Data

A series of cardiometabolic-related news items has been observed from Biomea Fusion, AstraZeneca, Ionis Pharmaceuticals, Hanmi Pharmaceuticals, Fractyl Health, and MannKind. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Zealand Topline Dapiglutide Data; Scholar Rock Ph2 Combination Trial Results; Mineralys Ph2 Topline Data in CKD; Biomea Preclinical Oral GLP-1RA Data

A series of cardiometabolic-related news items has been observed from Zealand Pharma, Scholar Rock, Mineralys Therapeutics, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Vertex, Biomea, and Esperion Q1 ‘25 Earnings; Oura Launches Glucose Feature

A series of cardiometabolic-related news items has been observed from Vertex Pharmaceuticals, Oura, Biomea Fusion, and Esperion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Biomea Q4 ‘24 Earnings; Gubra Ph1 GUBamy Trial Updates; Sernova Ph1/2 Cell Pouch Study Updates; Updated SAB Q4 ’24 Earnings

A series of cardiometabolic-related news items has been observed from Biomea Fusion, Gubra, Sernova Biotherapeutics, and SAB BIO. Below, FENIX provides highlights and insights for the respective news items, including an updated topic from yesterday’s blast.

This content is for Read Less members only.

Already a member? Log in here

Novo Buys Triple Agonist and Expands Wegovy Savings Program; Biomea Presents Data at ATTD 2025; March CHMP Agenda

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Biomea Fusion, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

JPM 2025 Day 3: PODD, MDGL, BMEA, IONS, SANA; Novo Wins PRV; Mounajro DTC; Lexaria Oral Liraglutide; Wisp Sublingual Sema

On the third day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Insulet, Madrigal, Biomea Fusion, Ionis, and Sana Biotechnology. Separately, a series of CVRM-related news items has been observed:

This content is for members only.

Already a member? Log in here

Dexcom Integrates AI Into Stelo; Biomea Topline Icovamenib T2DM Data

Two cardiometabolic-related news items have been observed: Dexcom announced it is integrating Generative AI (GenAI) into its Stelo CGM platform to analyze individual health data patterns (view press release); and Biomea Fusion announced positive topline results from the ongoing COVALENT-111 study in T2DM (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Dexcom and Oura Partnership; Novo ESSENCE Data at AASLD; Medtronic CY Q3 ’24 (FY Q2 ’25) Earnings; Silence, Esperion, NewAmsterdam, and Arrowhead Data at AHA 2024; Aligos Ph2 MASH Data; Biomea COVALENT-111 Analysis

A series of cardiometabolic-related news items have been observed from Dexcom, Novo Nordisk, Medtronic, Silence Therapeutics, Aligos Therapeutics. Biomea Fusion, Esperion, NewAmsterdam Pharma, and Arrowhead. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Zynquista Negative Adcom Vote; Novo STEP-9 Results Published; Wegovy Removed from FDA Shortage List; Amgen, Madrigal, Biomea, Teladoc, and Amarin Q3 ’24 Earnings; BI/Gubra Discontinue NPY2 for Obesity; Inventiva Positive DMC Recommendation for Ph3 MASH Trial

A series of cardiometabolic-related news items have been observed from Lexicon, Novo Nordisk, Amgen, Madrigal, Biomea Fusion, BI/Gubra, Inventiva, Teladoc, and Amarin. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Oral Semaglutide T2DM CVOT Data; Lilly Ph3 Orforglipron OSA Trial; Additional Calls to Block Novo-Catalent Acquisition; Lilly Partners for Obesity Awareness; Biomea Names BMF-219 “Icovamenib”

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Lilly, Novo/Catalent, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here